Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERYC 125 vs LYGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-t RNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.
Treatment of infections caused by susceptible strains of microorganisms (e.g., respiratory tract infections, skin infections, pertussis, diphtheria, syphilis),Off-label: Prokinetic agent for gastroparesis, treatment of delayed gastric emptying
No approved medical indications (Schedule I controlled substance in US),Investigational use in psychotherapy for anxiety, depression, and addiction (off-label)
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
For adults, administer 500 mg orally twice daily with or without food.
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
12 hours; prolonged to 24 hours in severe renal impairment (Cr Cl <30 m L/min)
Primarily hepatic via cytochrome P450 3A4 (CYP3A4) isoenzyme; undergoes demethylation and hydrolysis; major metabolite is desosamine.
Primarily hepatic via CYP450 enzymes, including CYP3A4 and CYP2D6; undergoes N-demethylation, N-deethylation, and hydroxylation.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Renal (90% as unchanged drug), biliary/fecal (10%)
70-90% bound to albumin and alpha-1-acid glycoprotein.
85% bound to albumin
0.5-0.9 L/kg; indicates distribution into total body water with some tissue binding.
1.5 L/kg (reflects extensive tissue distribution)
Oral: ~35% (acid-labile, enteric-coated).
Oral: 70-80% (first-pass metabolism reduces from 90% intrinsic absorption)
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce dose by 50% or extend interval to every 8-12 hours.
For GFR 30-89 m L/min: 500 mg orally once daily. For GFR <30 m L/min or on hemodialysis: 250 mg orally once daily. Administer after dialysis on dialysis days.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50%. Class C: reduce dose by 75% or avoid use.
Child-Pugh A and B: No adjustment necessary. Child-Pugh C: Contraindicated; do not use.
30-50 mg/kg/day orally divided every 6-8 hours; maximum 2 g/day.
For children 2-12 years: 10 mg/kg orally twice daily; maximum 500 mg per dose. For children 12-18 years: Administer as adult dose.
No specific adjustment; monitor for ototoxicity and QT prolongation; consider lower initial dose due to age-related renal decline.
Initiate at 250 mg orally twice daily for patients ≥65 years. Titrate to 500 mg twice daily as tolerated. Monitor renal function closely.
No FDA boxed warning for ERYC 125.
Not applicable; no FDA-approved indications and no FDA boxed warnings exist for LSD.
Risk of QT prolongation and ventricular arrhythmias (e.g., torsades de pointes), especially with other QT-prolonging drugs or electrolyte abnormalities,Hepatic impairment: monitor liver function,Potential for drug interactions via CYP3A4 inhibition,May exacerbate myasthenia gravis,Infantile hypertrophic pyloric stenosis (IHPS) risk in neonates
Risk of severe psychological distress, prolonged psychosis, hallucinogen persisting perception disorder (HPPD), and suicide.,May exacerbate psychiatric conditions; use only under strict medical supervision in research settings.,Potential for serotonin syndrome when combined with serotonergic drugs.
Hypersensitivity to erythromycin or any macrolide antibiotic,Concomitant use with CYP3A4 substrates that prolong QT interval (e.g., terfenadine, astemizole, cisapride, pimozide),Pre-existing QT prolongation or cardiac arrhythmia history
History of schizophrenia or psychotic disorder,Severe cardiovascular disease,Uncontrolled hypertension,Pregnancy and breastfeeding,Concurrent use with MAOIs or other serotonergic drugs
Grapefruit and grapefruit juice should be avoided as they can increase drug levels and risk of toxicity. Food does not significantly alter absorption of the ethylsuccinate formulation, but taking with a high-fat meal may slightly delay absorption. Avoid alcohol as it may increase risk of hepatotoxicity.
No specific food interactions are documented for LYGEN. It can be taken with or without food. However, grapefruit juice may theoretically affect CYP3A4 metabolism, but clinical significance is minimal. Alcohol should be avoided due to additive CNS depression.
Erythromycin, including ERYC 125, has not been associated with major congenital malformations in human studies. However, there is a potential increased risk of pyloric stenosis in infants exposed in utero or postnatally. No known teratogenic effects in first trimester; use in pregnancy is generally considered safe when indicated, especially for infections like chlamydia or syphilis.
No human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: avoid unless benefit outweighs risk; second/third trimester: limited data, use caution.
Erythromycin is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. It is considered compatible with breastfeeding by the American Academy of Pediatrics, but may increase the risk of pyloric stenosis in neonates. Monitor for gastrointestinal symptoms in the infant.
No data on excretion in human milk; M/P ratio unknown; caution in breastfeeding women due to potential for adverse effects in nursing infants.
No specific dose adjustment is required for pregnancy based on pharmacokinetic changes. However, erythromycin has reduced plasma concentrations in late pregnancy due to increased volume of distribution and clearance, but no dose adjustment is recommended. Standard dosing is used.
No established dosing adjustments; pharmacokinetics may be altered, requiring therapeutic drug monitoring if applicable; consult specialist for individualized dosing.
ERYC 125 (erythromycin ethylsuccinate) is a macrolide antibiotic; note that it may prolong QT interval, especially when combined with other QT-prolonging drugs. Avoid use in patients with hepatic impairment or known cholestatic jaundice. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption, but food does not significantly affect the ethylsuccinate formulation.
LYGEN (lacosamide) is a third-generation antiepileptic drug that selectively enhances slow inactivation of voltage-gated sodium channels. Key pearls: 1) Titrate slowly (50 mg BID weekly) to minimize CNS side effects like dizziness and ataxia. 2) Dose adjustment needed for Cr Cl <30 m L/min (max 300 mg/day). 3) Can cause PR interval prolongation; avoid in patients with second- or third-degree AV block. 4) Contraindicated in severe hepatic impairment (Child-Pugh C). 5) Available as oral tablets, oral solution, and IV; IV to oral conversion 1:1.
Take exactly as prescribed; do not skip doses or stop early even if you feel better.,Take this medication on an empty stomach, at least 1 hour before or 2 hours after a meal.,Avoid grapefruit and grapefruit juice while taking this medicine.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe stomach pain.,Notify your doctor immediately if you experience irregular heartbeat, fainting, or severe diarrhea.,Complete the full course to prevent antibiotic resistance.
Take LYGEN exactly as prescribed; do not suddenly stop taking it without talking to your doctor, as this can increase seizure frequency.,You may experience dizziness or blurred vision, especially at the start of treatment; avoid driving or operating heavy machinery until you know how the medication affects you.,LYGEN can cause a slow heart rate or fainting; tell your doctor if you have a history of heart problems or if you feel your heart beating slowly or irregularly.,Do not drink alcohol while taking LYGEN, as it may worsen side effects like drowsiness and dizziness.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERYC 125 vs LYGEN, answered by our medical review team.
ERYC 125 is a Macrolide Antibiotic that works by Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-t RNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.. LYGEN is a Estrogen that works by Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERYC 125 and LYGEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERYC 125 is: 250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.. The standard adult dose of LYGEN is: For adults, administer 500 mg orally twice daily with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERYC 125 and LYGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERYC 125 is classified as Category C. Erythromycin, including ERYC 125, has not been associated with major congenital malformations in human studies. However, there is a potential increased risk of pyloric stenosis in . LYGEN is classified as Category C. No human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: avoid unless benefit outweighs risk; second/third trimester: limited data, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.